Targeting the intestinal L-cell for obesity and type 2 diabetes treatment
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. / Albrechtsen, Nicolai Jacob Wewer; Kuhre, Rune Ehrenreich; Deacon, Carolyn F.; Holst, Jens Juul.
In: Expert Review of Endocrinology & Metabolism, Vol. 9, No. 1, 01.01.2014, p. 61-72.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Targeting the intestinal L-cell for obesity and type 2 diabetes treatment
AU - Albrechtsen, Nicolai Jacob Wewer
AU - Kuhre, Rune Ehrenreich
AU - Deacon, Carolyn F.
AU - Holst, Jens Juul
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, L-cell targeting might cause release of several hormones at the same time, providing additive effects on appetite and glucose regulation. In this review, we explore the role of proglucagon-derived peptides and other L-cell co-localizing hormones, in appetite regulation and the mechanism regulating their secretion.
AB - Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, L-cell targeting might cause release of several hormones at the same time, providing additive effects on appetite and glucose regulation. In this review, we explore the role of proglucagon-derived peptides and other L-cell co-localizing hormones, in appetite regulation and the mechanism regulating their secretion.
KW - appetite regulation
KW - gut hormones
KW - gut-brain axis
KW - L-cell
KW - obesity
U2 - 10.1586/17446651.2014.862152
DO - 10.1586/17446651.2014.862152
M3 - Journal article
AN - SCOPUS:84893138518
VL - 9
SP - 61
EP - 72
JO - Expert Review of Endocrinology and Metabolism
JF - Expert Review of Endocrinology and Metabolism
SN - 1744-6651
IS - 1
ER -
ID: 129244994